囊胚期与卵裂期胚胎移植提高卵母细胞受赠者的累积活产率、缩短时间并降低成本:一项随机对照试验
单中心随机对照试验纳入134例卵母细胞受赠者,随机分为第3天卵裂期移植组(n=69)和第5天囊胚期移植组(n=65),主要结局为12个月内累积活产率。第5天移植使累积活产率相对增加15.9%,活产时间显著缩短,达到50%累积活产率所需时间第3天组比第5天组多6个月(15.3个月 vs 8.9个月),平均每活产费用第3天策略比第5天策略高24%(14817.10欧元 vs 10959.20欧元)。
要点
- 第5天囊胚移植较第3天卵裂期移植使累积活产率相对增加15.9%。
- 达到50%累积活产率,第3天组需15.3个月,第5天组需8.9个月。
- 平均每活产费用第3天策略为14817.10欧元,比第5天策略的10959.20欧元高24%。
核心结论
- 在卵母细胞受赠者中,与卵裂期胚胎移植相比,囊胚期胚胎移植可提高临床妊娠率和活产率、缩短妊娠时间并降低活产成本,因此优选囊胚期移植。
研究设计与样本
- 单中心随机对照试验,于2017年4月至2018年8月开展。
- 纳入134例卵母细胞受赠者,随机分为第3天卵裂期移植组(n=69)和第5天囊胚期移植组(n=65)。
- 纳入标准为年龄18-50岁、处于第一次或第二次同步周期。
- 主要结局为自首次胚胎移植起12个月内的累积活产率,计入新鲜及后续冷冻移植;同时分析活产时间和每活产费用。
主要发现
- 第5天移植使累积活产率相对增加15.9%,活产时间较第3天移植显著缩短。
- 达到50%累积活产率,第3天组需15.3个月,第5天组需8.9个月,第3天组比第5天组多6个月。
- 平均每活产费用第3天策略为14817.10欧元,第5天策略为10959.20欧元,第3天策略比第5天策略高24%。
- 第3天组临床妊娠率比第5天组低25%。
- 因第3天组初期结果不佳而进行非计划中期分析后,试验提前终止。
临床怎么用
- 作者认为,在卵母细胞受赠者中优选囊胚期胚胎移植,因其临床妊娠率和活产率更高、妊娠时间更短且活产成本更低。
局限性
- 因第3天组初期结果不佳而进行非计划中期分析后,试验提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does embryo transfer day (day 5 versus day 3) affect cumulative live birth rates (CLBR), time to live birth (TLB) and cost per live birth (CPL) in recipients of donated oocytes? STUDY DESIGN: A single-centre RCT conducted between April 2017 and August 2018. Recipients of donated oocytes were randomized to cleavage-stage (day 3) or to blastocyst-stage (day 5) embryo transfer. Eligible recipients were aged 18-50 years and in their first or second synchronous cycle. Primary outcome was CLBR (12 months from first embryo transfer), and fresh and subsequent cryopreserved transfers were considered; TLB and CPL were also analysed. RESULTS: Recipients (n = 134) were randomized to the day-3 group (n = 69) or to the day-5 group (n = 65). Day-5 transfer resulted in a 15.9% relative increase in CLBR and a significant shorter TLB compared with day-3 transfer. To reach a 50% CLBR, the day-3 group required 6 months more than the day-5 group (15.3 versus 8.9 months, respectively). The average CPL in the day-3 strategy cost 24% more than the day-5 strategy (€14817.10 versus €10959.20). Clinical pregnancy rate was 25% less in the day-3 group. The trial was prematurely stopped after poor initial results in the day-3 arm led to unplanned interim analysis. CONCLUSIONS: The transfer of blastocyst-stage embryos in recipients of donated oocytes is preferred as it leads to a higher clinical pregnancy rate, live birth rate, shorter time to pregnancy and lower costs to achieve live birth, compared with cleavage-stage embryo transfer.
引用
- Clua E, Rodríguez I, Arroyo G, et al. Blastocyst versus cleavage embryo transfer improves cumulative live birth rates, time and cost in oocyte recipients: a randomized controlled trial. Reprod Biomed Online. 2022. PMID: 35430119. doi:10.1016/j.rbmo.2022.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。